Our approach guided our modeling of the impact of glycosylation on pancreatic cancer, enabling the testing of ST6GAL1 in the KC mouse model and identifying it as a promoter of this disease. This evidence concerns the gene ST6GAL1 and familial pancreatic carcinoma.